PUMA BIOTECHNOLOGY, INC.
Income Statement
| Line Item | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59.5M | $45.7M | $55.4M | $46.2M | $53.4M | $98.2M | $52.6M | $50.8M |
| Cost of Revenue | $14.9M | $10.8M | $11.9M | $10.3M | $12.0M | $29.6M | — | $9.9M |
| Gross Profit | $44.6M | $34.9M | $43.5M | $36.0M | $41.4M | $68.6M | — | $40.8M |
| Gross Margin | 74.9% | 76.3% | 78.5% | 77.8% | 77.6% | 69.9% | — | 80.4% |
| Operating Expenses | ||||||||
| Research & Development | $12.0M | $15.2M | $14.2M | $18.8M | $18.6M | $20.2M | $24.2M | $23.3M |
| SG&A Expense | $20.6M | $20.4M | $22.6M | $26.1M | $39.4M | $28.2M | $28.6M | $29.6M |
| Operating Income | $12.1M | $-747.0K | $6.7M | $-9.0M | $-16.6M | $20.1M | $-11.1M | $-12.1M |
| Operating Margin | 20.3% | -1.6% | 12.2% | -19.4% | -31.2% | 20.5% | -21.2% | -23.9% |
| Interest Expense | $2.7M | $2.7M | $2.7M | $3.1M | $3.5M | $3.5M | $3.6M | $3.6M |
| Pretax Income | $9.4M | $-3.4M | $4.3M | $-44.6M | $-5.1M | $16.6M | $-14.8M | $-31.5M |
| Income Tax Expense | $57.0K | $37.0K | $211.0K | $37.0K | $38.0K | $38.0K | — | $0 |
| Net Income | $9.4M | $-3.4M | $4.1M | $-44.7M | $-5.1M | $16.5M | $-15.0M | $-31.5M |
| Net Margin | 15.7% | -7.4% | 7.4% | -96.6% | -9.6% | 16.8% | -28.5% | -62.0% |
| EPS (Basic) | $0.21 | $-0.08 | $0.09 | $-1.09 | $-0.13 | $0.41 | $-0.38 | $-0.79 |
| EPS (Diluted) | $0.21 | $-0.08 | $0.10 | $-1.09 | $-0.13 | $0.40 | $-0.38 | $-0.79 |
| Shares Outstanding (Basic) | 45.1M | 42.2M | 40.6M | 40.8M | 40.5M | 40.3M | 39.9M | 39.7M |
| Shares Outstanding (Diluted) | 45.4M | 42.2M | 40.6M | 40.8M | 40.5M | 40.9M | 39.9M | 39.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |